Literature DB >> 25413956

Aceruloplasminemia: neurodegeneration with brain iron accumulation (NBIA) associated with parkinsonism.

L H P Vroegindeweij1, A J W Boon, J H P Wilson, J G Langendonk.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25413956     DOI： 10.1007/s10545-014-9793-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  4 in total

1.  Aceruloplasminemia with a novel mutation associated with parkinsonism.

Authors:  S Kohno; H Miyajima; Y Takahashi; Y Inoue
Journal:  Neurogenetics       Date:  2000-03       Impact factor: 2.660

Review 2.  Parkinsonism and inborn errors of metabolism.

Authors:  A Garcia-Cazorla; S T Duarte
Journal:  J Inherit Metab Dis       Date:  2014-06-07       Impact factor: 4.982

Review 3.  The neurological presentation of ceruloplasmin gene mutations.

Authors:  Alisdair McNeill; Massimo Pandolfo; Jens Kuhn; Huifang Shang; Hiroaki Miyajima
Journal:  Eur Neurol       Date:  2008-07-30       Impact factor: 1.710

4.  Aceruloplasminemia, an inherited disorder of iron metabolism.

Authors:  Hiroaki Miyajima; Yoshitomo Takahashi; Satoshi Kono
Journal:  Biometals       Date:  2003-03       Impact factor: 2.949
  4 in total
  3 in total

1.  The Ferroxidase Hephaestin But Not Amyloid Precursor Protein is Required for Ferroportin-Supported Iron Efflux in Primary Hippocampal Neurons.

Authors:  Changyi Ji; Brittany L Steimle; Danielle K Bailey; Daniel J Kosman
Journal:  Cell Mol Neurobiol       Date:  2017-11-25       Impact factor: 5.046

Review 2.  Inborn errors of metabolism associated with hyperglycaemic ketoacidosis and diabetes mellitus: narrative review.

Authors:  Majid Alfadhel; Amir Babiker
Journal:  Sudan J Paediatr       Date:  2018

3.  Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia.

Authors:  Alan Zanardi; Antonio Conti; Marco Cremonesi; Patrizia D'Adamo; Enrica Gilberti; Pietro Apostoli; Carlo Vittorio Cannistraci; Alberto Piperno; Samuel David; Massimo Alessio
Journal:  EMBO Mol Med       Date:  2018-01       Impact factor: 12.137
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.